Collegium Q1 revenue up 23% to $177.8M; guides FY25 $735-750M; authorizes $25M ASR

COLLEGIUM PHARMACEUTICAL, INC

2025-Q1 EPS reported $0.07 revenue$177,757,000

Q1 net revenue $177.8M (+23% YoY); Jornay PM $28.5M (+24% Rx growth); pain portfolio $149.2M (+3%).
GAAP net income $2.4M ($0.07 diluted EPS); non-GAAP adj. net income $57.4M ($1.49 adj. EPS).
Adjusted EBITDA $95.2M (+3% YoY); cash & securities $197.8M, up from $162.8M at Dec 31, 2024.
Board authorized $25M accelerated share repurchase; paid down $16.1M in debt during Q1.
Expanded Jornay PM sales force to ~180 reps; new Chairman, board members, and execs appointed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.